Carasent (Q3 Initial take): Largely as expected, with substantial margin improvements - Redeye
Redeye sees a solid Q3 report from Carasent with slightly lower ARR growth but better cost control than expected. We will most likely retain our positive view and expect minor changes to our Base Case and forecasts.
ANNONS
Redeye sees a solid Q3 report from Carasent with slightly lower ARR growth but better cost control than expected. We will most likely retain our positive view and expect minor changes to our Base Case and forecasts.
